IceCure Medical Ltd (ICCM)
NASDAQ: ICCM · Real-Time Price · USD
1.070
+0.085 (8.63%)
At close: Jul 25, 2025, 4:00 PM
1.060
-0.010 (-0.93%)
After-hours: Jul 25, 2025, 7:59 PM EDT
IceCure Medical Revenue
IceCure Medical had revenue of $725.00K in the quarter ending March 31, 2025, a decrease of -2.42%. This brings the company's revenue in the last twelve months to $3.27M, up 0.34% year-over-year. In the year 2024, IceCure Medical had annual revenue of $3.29M with 1.92% growth.
Revenue (ttm)
$3.27M
Revenue Growth
+0.34%
P/S Ratio
17.52
Revenue / Employee
$49,591
Employees
66
Market Cap
73.51M
Revenue Chart
Revenue History
Fiscal Year End | Revenue | Change | Growth |
---|---|---|---|
Dec 31, 2024 | 3.29M | 62.00K | 1.92% |
Dec 31, 2023 | 3.23M | 144.00K | 4.67% |
Dec 31, 2022 | 3.09M | -1.05M | -25.45% |
Dec 31, 2021 | 4.14M | 270.00K | 6.98% |
Dec 31, 2020 | 3.87M | 2.21M | 132.76% |
Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Dec 31, 2015 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Sources: Historical revenue is based on company filings submitted to the U.S. Securities and Exchange Commission (SEC). The most recent revenue numbers may be taken from company press releases.
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Full DefinitionRelated Stocks
Company Name | Revenue |
---|---|
UnitedHealth Group | 410.06B |
Johnson & Johnson | 90.63B |
Merck & Co. | 63.92B |
AbbVie | 57.37B |
Novartis AG | 55.19B |
AstraZeneca | 54.98B |
Eli Lilly and Company | 49.00B |
Novo Nordisk | 43.92B |
ICCM News
- 1 day ago - IceCure's ProSense® Featured at Japanese Breast Cancer Society Conference: Updated Positive Clinical Data Shows 99% Recurrence Free Rate with Cryoablation - PRNewsWire
- 2 days ago - IceCure Reminds Shareholders of Upcoming Expiration of Rights Offering Subscription Period - PRNewsWire
- 16 days ago - IceCure Announces Commencement of Rights Offering - PRNewsWire
- 23 days ago - IceCure Reports Preliminary Financial Results for the Three and Six Months Ended June 30, 2025 - PRNewsWire
- 4 weeks ago - IceCure Announces Record Date for Rights Offering for Up to $10 Million - PRNewsWire
- 6 weeks ago - IceCure Receives Notice of Patent Allowance in U.S. for a Novel Cryogen Flow Control to Optimize Patient Outcomes - PRNewsWire
- 2 months ago - IceCure Medical Ltd (ICCM) Q1 2025 Earnings Call Transcript - Seeking Alpha
- 2 months ago - IceCure Medical Reports First Quarter 2025 Financial Results - PRNewsWire